Repros up on Phase III Androxal data

Repros Therapeutics Inc. (NASDAQ:RPRX) gained $2.59 (12%) to $23.85 on Tuesday after once-daily oral Androxal enclomiphene met the co-primary endpoints in 181 men in the intent-to-treat (ITT) populati...